Codexis, Inc.

Albany Molecular Research, Inc.

Telik, Inc.

E-therapeutics Plc

Steven James Collier

Derek J Smith

Oscar Alvizo

Wan Lin Yeo

Joly Sukumaran

Haibin Chen

Shiwei Song

Junye Xu

Gjalt W Huisman

Jovana Nazor

Robert John Wilson

Jacob M Janey

Jeffrey C Moore

Fabien Louis Cabirol

Yong Koy Bong

Scott J Novick

Anupam Gohel

Behnaz Behrouzian

Emily Mundorff

Gregory Hughes

Michael D Clay

Nicholas John Agard

Stefanie Ng Minor

Gregory Allan Cope

Ee Ling Teo

Jun Zhu

Naga K Modukuru

Michael A Crowe

Ellen D Eberhard

Ee Lui Ang

Magnus Widegren

Jagadeesh Mavinahalli

Fu Fan

Christopher K Savile

John M Gruber

Lynne Gilson

Birgit Kosjek

Michael Vogel

Seong Ho Oh

Wenjuan Zha

Hans-Georg Joerg Hennemann

Yang Hong

Helen Hsieh

Weng Lin Tang

Son Pham

Martina Quintanar-Audelo

Thomas Daussmann

Tao Li

Anupam Gohel Prafulchandra

Xiyun Zhang

Vesna Mitchell

Benjamin Mijts

Brian Wong

Harold Meckler

David C Burdick

Derek Smith

Betina Biolatto

Jian Ding

Jack S Liang

Steven R Schow

Bernhard J Paul

Artis Klapars

William Allen Boulanger

Gregory L Beutner

John Limanto

Pavel E Zhichkin

Brendan T Grau

R Jason Herr

Matthew Truppo

Eric Ashley

Dennis L Edie

Marissa Mock

Ronan Y Guevel

Pedro E Hernandez Abad

Mark A Helle

Hallena R Strotman

Stephen A Eastham

Hans J Kjaersgaard

Robert E Polomski

Frédéric Jos

Alicia J Habershaw

James Thomson Loch, Iii

Robert Wilson

Vijaya Bhasker Gondi

Nicholas John Holman

Fan Jaslyn Fu

Joerg Hennemann

Robert J Wilson

The present disclosure provides engineered transaminase polypeptides for the production of amines, polynucleotides encoding the engineered transaminases, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases to prepare compounds useful in the production of active pharmaceutical agents.

Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs

The present disclosure provides acyltransferases useful for synthesizing therapeutically important statin compound.

Variant LovD polypeptides and their uses

The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize a variety of chiral compounds. The engineered ketoreductase polypeptides are optimized for catalyzing the conversion of N-methyl-3-keto-3-(2-thienyl)-1-propanamine to (S)—N-methyl-3-hydroxy-3-(2-thienyl)-1-propanamine.

Engineered ketoreductase polypeptides

The present invention relates to non-naturally occurring polypeptides useful for preparing armodafinil, polynucleotides encoding the polypeptides, and methods of using the polypeptides. The non-naturally occurring polypeptides of the present invention are effective in carrying out biocatalytic conversion of the (i) 2-(benzhydrylsulfinyl)acetamide to (−)-2-[(R)-(diphenylmethyl)sulfinyl]acetamide (armodafinil), or (ii) benzhydryl-thioacetic acid to (R)-2-(benzhydrylsulfinyl)acetic acid, which is a pivotal intermediate in the synthesis of armodafinil, in enantiomeric excess.

Biocatalysts and methods for the synthesis of armodafinil

Engineered biocatalysts and methods for synthesizing chiral amines

The present disclosure provides engineered proline hydroxylase polypeptides for the production of hydroxylated compounds, polynucleotides encoding the engineered proline hydroxylases, host cells capable of expressing the engineered proline hydroxylases, and methods of using the engineered proline hydroxylases to prepare compounds useful in the production of active pharmaceutical agents.

Biocatalysts and methods for hydroxylation of chemical compounds

The present disclosure relates to engineered ketoreductase polypeptides for the preparation of hydroxyl substituted carbamate compounds, and polynucleotides, vectors, host cells, and methods of making and using the ketoreductase polypeptides.

Biocatalysts for the preparation of hydroxy substituted carbamates

The present disclosure relates to non-naturally occurring polypeptides useful for preparing Ezetimibe, polynucleotides encoding the polypeptides, and methods of using the polypeptides.

Biocatalysts for ezetimibe synthesis

Methods for the improved acylation of chemical substrates using LovD acyltransferases, thioesters having acyl groups, and (i) thiol scavengers and/or (ii) precipitating agents are presented. An improved method for the production of simvastatin using (i) activated charcoal as a thiol scavenger and/or (ii) ammonium hydroxide as a precipitating agent is also presented.

Lov-D acyltransferase mediated acylation

The disclosure relates to engineered ketoreductase polypeptides and processes of using the polypeptides for production of phenylephrine.

Ketoreductase polypeptides for the preparation of phenylephrine

The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.

Engineered imine reductases and methods for the reductive amination of ketone and amine compounds

Growing community of inventors

Concord, MA, United States of America

Steven James Collier